P559: Humoral Response to Mrna-Based Covid-19 Vaccine in Patients With Myeloid Malignancies

Abstract

Background: Background:The end of the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease-19 (COVID-19), is not foreseen. Vaccination using two subtypes of mRNA-based vaccines, BNT162b2 or mRNA-1273, is an effective public health measure to reduce the risk of infection and severe complications from COVID-19. However, COVID-19 vaccine response data for patients with myeloid malignancy, who are at severe risk in case of infection, has not emerged.

Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis

“…Another possible interpretation lies in the patients included in this meta-analysis had a variety of hematologic disorders with varying disease states. Previous studies have demonstrated that patients with hematologic disorders react to COVID-19 vaccination in a variable manner, depending on type and activity level of the disorder [56][57][58]. However, the information of specific diagnosis for individual patients were lacking for most studies.…”

Antibody responses to SARS‐CoV‐2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti‐cancer therapies

“…Encouraging seroconversion rates to SARS‐CoV‐2 vaccination in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) patients have been reported in large cohort studies 1 , 2 , 3 , 4 ; however, the majority of these patients were not receiving active systemic anti‐cancer therapy (SACT) and its impact on vaccine responses remains to be fully elucidated. Mori et al 5 report seroconversion rates of 94.7 and 100% respectively in Japanese patients with AML and MDS after two doses of mRNA SARS‐CoV‐2 vaccine, of which 39% received SACT. We report SARS‐CoV‐2 antibody responses following vaccination in a UK cohort of AML and HR‐MDS patients all receiving, or having recently completed SACT, and stratified by prior SARS‐CoV‐2 infection.…”

“…Mori et al reported lower antibody titres after two doses in those AML/MDS patients receiving active SACT as treatment or maintenance therapy (the majority received HMA) compared to those receiving non‐chemotherapeutic treatments or completed treatment. 5 We observed that no significant difference in seropositivity or anti‐S titres was seen in AML patients receiving intensive (28%) compared to non‐intensive chemotherapy (21%); however, anti‐S titres were significantly reduced in venetoclax‐based regimens (55% AML patients, 33% HR‐MDS, median 158.5 U/ml [IQR 34.85–873], p = 0.04), independent of previous SARS‐CoV‐2 infection (Figure 1E,F ). Reduced serological responses in patients receiving venetoclax have been previously reported in mature B cell neoplasms and myeloma, but not in AML or MDS.…”

Is COVID vaccine effective in patients with myeloid malignancy?

“…A partial answer to the question of the outcome in patients with myeloid neoplasms is provided in this issue of the British Journal of Haematology 13 . Dr. Akio Mori and colleagues from Japan, report their experience with the humoral response to COVID vaccination in patients with myeloid disorders.…”